| Recruiting | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Childre NCT06987539 | Amgen | Phase 2 |
| Recruiting | A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravu NCT07221838 | Alexion Pharmaceuticals, Inc. | Phase 4 |
| Recruiting | ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Particip NCT07284420 | argenx | Phase 2 |
| Recruiting | ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens i NCT07294170 | argenx | — |
| Recruiting | Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG) NCT07215650 | Candid Therapeutics | Phase 1 |
| Recruiting | Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis NCT06967480 | Alexion Pharmaceuticals, Inc. | — |
| Recruiting | Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myastheni NCT07039916 | Immunovant Sciences GmbH | Phase 3 |
| Recruiting | Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis NCT06704269 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Recruiting | A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients NCT06744920 | Novartis Pharmaceuticals | Phase 3 |
| Enrolling By Invitation | An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized M NCT06435312 | UCB Biopharma SRL | Phase 3 |
| Recruiting | PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Grav NCT06607627 | Alexion Pharmaceuticals, Inc. | Phase 3 |
| Recruiting | A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis NCT06055959 | UCB Biopharma SRL | Phase 2 / Phase 3 |
| Enrolling By Invitation | An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With NCT06540144 | UCB Biopharma SRL | Phase 3 |
| Recruiting | KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia NCT06193889 | Kyverna Therapeutics | Phase 2 / Phase 3 |
| Completed | A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Genera NCT06471361 | UCB Biopharma SRL | Phase 3 |
| Recruiting | A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Parti NCT06517758 | Novartis Pharmaceuticals | Phase 3 |
| Recruiting | A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) NCT06456580 | Vor Biopharma | Phase 3 |
| Recruiting | A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis. NCT06447597 | Shanghai Jiaolian Drug Research and Development Co., Ltd | Phase 2 / Phase 3 |
| Recruiting | A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myastheni NCT06392386 | argenx | Phase 2 / Phase 3 |
| Recruiting | Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With General NCT06463587 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Phase 3 |
| Recruiting | A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Grav NCT06149559 | UCB Biopharma SRL | Phase 2 / Phase 3 |
| Active Not Recruiting | A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor NCT06298552 | argenx | Phase 3 |
| Recruiting | Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Myasthenia Gravis NCT06064695 | University of Missouri-Columbia | N/A |
| Active Not Recruiting | Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Ge NCT05644561 | Alexion Pharmaceuticals, Inc. | Phase 3 |
| Recruiting | Seronegative Myasthenia Gravis - Efgartigimod IV NCT06587867 | University Health Network, Toronto | Phase 3 |
| Completed | A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participant NCT05681715 | UCB Biopharma SRL | Phase 3 |
| Active Not Recruiting | Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis NCT05556096 | Alexion Pharmaceuticals, Inc. | Phase 3 |
| Completed | An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participa NCT05514873 | UCB Biopharma SRL | Phase 3 |
| Enrolling By Invitation | Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subc NCT05374590 | argenx | Phase 2 / Phase 3 |
| Active Not Recruiting | Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Pa NCT05403541 | Immunovant Sciences GmbH | Phase 3 |
| Terminated | Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis NCT05218096 | Alexion Pharmaceuticals, Inc. | Phase 2 |
| Withdrawn | Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis NCT04982289 | Alexion Pharmaceuticals, Inc. | Phase 2 |
| Completed | An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Pa NCT04980495 | argenx | Phase 3 |
| Active Not Recruiting | A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well Th NCT05070858 | Regeneron Pharmaceuticals | Phase 3 |
| Recruiting | Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Ch NCT04833894 | argenx | Phase 2 / Phase 3 |
| Terminated | A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With NCT04963270 | Hoffmann-La Roche | Phase 3 |
| Completed | Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patien NCT04818671 | argenx | Phase 3 |
| Completed | Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared NCT04735432 | argenx | Phase 3 |
| Completed | A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis NCT04650854 | UCB Biopharma SRL | Phase 3 |
| Active Not Recruiting | Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis NCT04225871 | UCB Biopharma SRL | Phase 3 |
| Recruiting | Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5IT NCT04202341 | Alexion Pharmaceuticals, Inc. | — |
| Completed | A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients W NCT04124965 | UCB Biopharma SRL | Phase 3 |
| Terminated | An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to NCT03896295 | Momenta Pharmaceuticals, Inc. | Phase 2 |
| Completed | A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis NCT03971422 | UCB Biopharma SRL | Phase 3 |
| Completed | A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administ NCT03772587 | Momenta Pharmaceuticals, Inc. | Phase 2 |
| Completed | Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis NCT03920293 | Alexion Pharmaceuticals, Inc. | Phase 3 |
| Completed | A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Wea NCT03770403 | argenx | Phase 3 |
| Completed | An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakne NCT03669588 | argenx | Phase 3 |
| Completed | Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis NCT03315130 | Ra Pharmaceuticals | Phase 2 |
| Completed | A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis NCT02950155 | Fredrik Piehl | Phase 3 |
| Completed | Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis NCT00515450 | Benesis Corporation | Phase 3 |